- $55.54m
- -$38.63m
- 24
- 44
- 11
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17.7 | 26.8 | 47.2 | 69 | 81 |
Operating Profit | -17.7 | -26.8 | -47.2 | -69 | -81 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.6 | -26.5 | -47 | -66.7 | -74.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.6 | -26.4 | -47 | -66.7 | -74.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -17.6 | -26.4 | -47 | -66.7 | -74.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -17.6 | -26.4 | -47 | -66.7 | -74.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -10.2 | -9.57 | -1.78 | -2.06 | -1.79 |